Four large cardiovascular outcomes trials, the EMPA­REG OUTCOME trial [15], the CANVAS Program 30 [19], the DECLARE-TIMI 58 trial [20] and the VERTIS CV [21] trial, have demonstrated a significant and consistent reduction in heart failure events with SGLT2 inhibitors. Here, SLC5A2 is linked to heart failure.